Could a targeted drug shrink advanced cervical tumors?
NCT ID NCT04205799
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This phase 2 trial tests the drug cabozantinib in women with advanced or metastatic cervical cancer that has worsened after platinum-based chemotherapy. The study aims to see if cabozantinib can control the disease and how safe it is, particularly regarding risks like fistulas. Participants take a daily 60 mg pill in 4-week cycles until the cancer progresses or side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cabozantinib
What this could lead to
If effective, cabozantinib could offer a new treatment option for advanced cervical cancer when standard chemotherapy stops working.
What could go wrong
This is a small, early-phase trial, so results may not confirm benefit. Cabozantinib can cause serious side effects like fistulas or perforations in the gut or urinary tract.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre François Baclesse
Caen, France
-
Centre Léon Bérard
Lyon, France
-
Centre Oscar LAMBRET
Lille, France
-
Institut CURIE
Saint-Cloud, France
-
Institut Gustave Roussy
Villejuif, France
-
Institut de Cancérologie de Montpellier
Montpellier, France
-
Institut de cancérologie de l'Ouest
Angers, France
-
Institut de cancérologie de l'Ouest
Nantes, France